Download PDF
1 / Pages

Other users also viewed these articles

Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis? Ana Martins; Sofia Pimenta; Daniela Oliveira; Rafaela Nicolau; Alexandra Bernardo; Teresa Martins Rocha; Lúcia Costa; Miguel Bernardes;
Reumatol Clin. 2024;20:380-5
Takotsubo Syndrome in a Rheumatoid Arthritis Patient Under Tofacitinib: A Case Report Salomé Garcia; Georgina Terroso; Elisabete Martins; Sofia Pimenta; Lúcia Costa; Miguel Bernardes;
Reumatol Clin. 2022;18:493-4
Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis José María Álvaro-Gracia Álvaro; Petra Díaz del Campo Fontecha; José Luis Andréu Sánchez; Alejandro Balsa Criado; Rafael Cáliz Cáliz; Isabel Castrejón Fernández; Hèctor Corominas; José A. Gómez Puerta; Sara Manrique Arija; Natalia Mena Vázquez; Ana Ortiz García; Chamaida Plasencia Rodríguez; Lucía Silva Fernández; Jesús Tornero Molina;
Reumatol Clin. 2024;20:423-39